Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676536 | 0.82 | SMN1; SMN2 (0.68) | CA12CA1CA9CA2CA3 | |
| SCHEMBL398044 | 0.82 | CNR2 (0.57) | CNR2SMN1; SMN2LMNAGLAGAA | |
| SCHEMBL4076826 | 0.82 | CA12 (0.57) | CA12CA1CA9CA2CA4 | |
| SCHEMBL3619711 | 0.82 | CNR2 (0.49) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL8602183 | 0.79 | CA12 (0.59) | CA12CA1CA9CA2CA3 | |
| SCHEMBL8906501 | 0.79 | NPC1 (0.45) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL3615482 | 0.78 | BMP1 (0.55) | SMN1; SMN2TAS2R14CXCR3LMNANPC1 | |
| SCHEMBL810965 | 0.78 | LMNA (0.70) | CA12CA1CA9CA2CA3 | |
| SCHEMBL11796461 | 0.77 | CA9 (0.53) | CA12CA1CA9CA2CA3 | |
| SCHEMBL9310747 | 0.77 | CNR2 (0.52) | CA12CA9CA2CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167479-B1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-8084606-B2 | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates | SYMED LABS LIMITED (IN) | 2011-12-27 | — | — | US | disclosed |
| EP-2167479-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | Symed Labs Limited (IN) | 2010-03-31 | — | — | EP | disclosed |
| US-20090281318-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| WO-2008152650-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281318-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | CYP3A5, TPH1, CYP51A1 | CA12 1392/4885CA1 1009/4885CA9 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.